Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes;L'étude clinique du mois: L'étude field de protection cardio-vasculaire avec le fénofibrate chez le patient diabétique de type 2

Revue Medicale de Liege

Volumn 60, Issue 12, 2005, Pages 957-961

  Radermecker, R P ^a,c   Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Service de Diabetologie Nutrition et Maladies Metaboliques   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cardiovascular; Coronary heart disease; Diabetes; Dyslipidaemia; Fenofibrate; Myocardial infarction; Prevention

Indexed keywords

FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ANTILIPEMIC AGENT;

ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; DRUG TOLERABILITY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; AGED; DYSLIPIDEMIA; MIDDLE AGED; MULTICENTER STUDY;

AGED; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; MIDDLE AGED; PROCETOFEN;

EID: 29944441641     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Scheen AJ, Van Gaal LF.- Le diabète de type 2 au coeur du syndrome métabolique: plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
2. Wallemacq C, Van Gaal LF, Scheen AJ.- Le coût du diabète de type 2: résumé de l'enquête européenne CODE-2 et analyse de la situation en Belgique. Rev Med Liège, 2005, 60, 278-284.
3. Paquot N, Scheen AJ.- Prévention cardio-vasculaire chez le patient diabétique de type 2. Rev Med Liège, 2003, 58, 271-27.
4. Ducobu J.- Dyslipidémie et diabète. Rev Med Liège, 2005, 60, 578-585.
5. Steiner G.- Fibrates in the metabolic syndrome and in diabetes. Endocrinol Metab Clin North Am, 2004, 33, 545-555.
6. Collins R, Armitage J, Parish S, et al.- MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet, 2002, 361, 2005-2016.
7. Colhoun HM, Betteridge DJ, Durrington PN, et al.- Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364, 685-696.
8. Gotto AM.- Lipid management in diabetic patients: lessons from prevention trials. Am J Med, 2002, 112 (Suppl 8A), 19S-26S.
9. The FIELD study investigators.- Effects of long-term fenofibrate therapy on cardiovacsular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, published online November 14, 2005.
10. Chinetti-Gbaguidi G, Fruchart JC, Staels B.- Pleiotropic effects of fibrates. Curr Atheroscler Rep, 2005, 7, 396-401.
11. Koskinen P, Mänttäri M, Manninen V, et al.- Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care, 1992, 15, 820-825.
12. Rubins HB, Robins SJ, Collins D, et al.- Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 2002, 162, 2597-2604.
13. The DAIS Group.- Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet, 2001, 357, 905-910.
14. Elkeles RS, Diamond JR, Poulter C, et al.- Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP). Diabetes Care, 1998, 21, 641-648.
15. Tenenbaum A, Motro M, Fisman EZ, et al.- Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med, 2005, 165, 1154-1160.
16. Colhoun H.- After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes? Lancet, 2005, published online November 14, 2005.
17. Scheen AJ.- Traitement de l'hyperlipidémie combinée: fibrate ou/et Staline? Rev Med Liège, 1999, 54, 583-587.